(photo: )

Fresenius Kabi acquires Merck’s biosimilar business

Fresenius Kabi is acquiring Akorn and Merck’s biosimilars business for $4.3 billion in a bid to strengthen and diversify its product portfolio.


  •  (photo: )

    Biogen report positive results for MS treatment

    Biogen has released data show that treatment with its flagship multiple sclerosis therapies – Tecfidera and Tysabri – may improve outcomes for sufferers if used early in the course of the disease.






 (photo: )

Pharma companies warn Europe will Trump England for new medicines

In a new snapshot survey of leading pharmaceutical businesses in the UK, companies have said that changes to the way the National Institute for Health & Care Excellence (NICE) and NHS England (NHSE) assess new medicines will decrease access to the latest treatments, with new medicines for cancer set to be impacted the most.

 (photo: )

NICE to fast-track more drug approvals

UK patients will benefit from access to the most cost-effective treatments nearly 5 months faster after changes to the NICE drug evaluation process were approved.


 (photo: )

Boon for medicines logistics with silica ‘cages’ breakthrough

Vaccines and antibodies could be transported and stored without refrigeration by capturing them in tiny silica ‘cages’, a discovery which could make getting vital medicines to remote or dangerous places much easier, cheaper and safer.

 (photo: )

Sobi enters new distribution agreement with Valeant for Ammonul

Swedish Orphan Biovitrum (Sobi) has entered into a 3-year agreement with Valeant Pharmaceuticals Ireland for the distribution of Ammonul injection in Europe, the Middle East and North Africa.


 (photo: )

Regeneron & Sanofi bag FDA approval for once monthly cholesterol injection

Regeneron Pharmaceuticals and Sanofi have gained US FDA approval for the companies’ new supplemental Biologics License Application for a once-monthly, 300 mg dose of Praluent Injection for adults with high low-density lipoprotein cholesterol.

 (photo: )

Paratek, Zai Lab partner to develop, commercialise antibiotic in China

Boston-based biopharma company, Paratek Pharmaceuticals, has entered into collaboration with Zai Lab to develop and commercialise of omadacycline for patients in China.